CLDN4 and ovarian carcinoma: Breed et al. showed that apoptosis was enhanced in Claudin-4–positive ovarian cancer cells when paclitaxel was combined with a Claudin-4–disrupting peptide, but not with cisplatin, suggesting drug-specific resistance mechanisms [25].